Seven-Country Facility Survey Measured Diazepam Stock on a Single Assessment Day

Having diazepam available at a facility is different from a patient being able to obtain and use it appropriately.

What the supplied source reports

The analysis pooled nationally representative facility surveys from seven countries conducted during 2012–2018. Among 7,958 facilities, estimated diazepam availability was 46.1%. Stock varied by country and facility characteristics, including level of care, ownership and resources.

Limits of the evidence

The surveys were snapshots. They did not establish continuous availability, affordability, access for an individual patient or prescribing competence. Only two psychotropic medicines were studied, so diazepam stock cannot summarize the entire mental-health formulary or current access.

Implications for forensic interpretation

For a medication-access inquiry, distinguish absent stock on one day from a prolonged supply interruption. Review the patient’s actual facility, dates, alternatives and dispensing records. The study describes historical system-level gaps and cannot establish that a particular clinical outcome was caused by lack of diazepam or that stocked medicine reached the patient.

Source and related reading

Source reviewed: Availability of two essential medicines for mental health in Bangladesh the Democratic Republic of C (PMC9339230). Forensic applications above are interpretive analysis of the supplied publication.

Related reading: A Febrile-Seizure Survey Found No Home Diazepam or Buccal Midazolam Use.